NCT01708993 - Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

December 10, 2012

Primary Completion Date

January 26, 2016

Study Completion Date

September 26, 2018

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed and Reolysin (and safety run-in)

Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

DRUG

Pemetrexed

Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks

DRUG

Docetaxel and Reolysin

Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

DRUG

Docetaxel

Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks

Trial Locations (12)

T2N 4N2

Tom Baker Cancer Centre, Calgary

V2S 0C2

BCCA - Abbotsford Centre, Abbotsford

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

L1G 2B9

Lakeridge Health Oshawa, Oshawa

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina